Neuroprotective effects of novel derivatives of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide in two brain ischemic models on mice

Japanese Journal of Anesthesiology

Volumn 54, Issue 3, 2005, Pages 240-248

  Takeda, Naoko ^a   Murozono, Michihiro ^a   Watanabe, Seigo ^a   Isshiki, Atsushi ^a   Watanabe, Yasuo ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Intraperitoneal injection; Neuro protection; New derivatives of VIP PACAP; PACAP; VIP

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IK 312548; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; ADCYAP1 PROTEIN, MOUSE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEMISPHERIC DOMINANCE; HIPPOCAMPUS; INHIBITION KINETICS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; POSTERIOR COMMUNICATING ARTERY; TREATMENT OUTCOME; ANIMAL; BRAIN CIRCULATION; C57BL MOUSE; CEREBRAL ARTERY DISEASE; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAPERITONEAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; HIPPOCAMPUS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 17144391521     PISSN: 00214892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fukui H, Fukui Y, Noguchi M, Kameyama Y, Isshiki A, Watanabe Y. Inhibitory effects of extracellular matrix modulator (s) on lipopolysaccharide (LPS)-and acidosis-damaged glia containing cerebellar granule cell cultures. Neurochem Res 2004; 29: 827-33.
2. Onoue S, Ohmori Y, Matsumoto A, Yamada S, Kimura R, Kashimoto K. Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP). Life Sci 2004; 74: 1465-77.
3. Urayama K, Yamada S, Kimura R, Zhang J, Watanabe Y. Neuroprotective effect and brain receptor binding of taltirelin, anovel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C 57 BL/6 J mice. Life Sci 2002; 72: 601-7.
4. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 2001; 7: 324-30.
5. Yang G, Kitagawa K, Matsushita K, Mabuchi T, Yagita Y, Matsumoto M, et al. C 57 BL/6 strain is most susceptible to cerebral ischemia following bilateral common carotid occlusion among seven mouse strains: selective neuronal death in the murine transient forebrain ischemia. Brain Res 1997; 752: 209-18.
6. Wellons III JC, Sheng H, Laskowitz DT, Mackensen G, Pearlstein R D, Warner D S. A comparison of strain-related susceptibility in two murine recovery models of global cerebral ischemia. Brain Res 2000; 868: 14-21.
7. CLINICAL NEUROSCIENCE 1999; 17: 18-21.
8. Onoue S, Endo K, Yajima T, Kashimoto K. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and eytotoxicity. Regul Pept 2002; 107: 43-47.
9. Brown DR. Neuronal release of vasoactive intestinal peptide is important to astrocytic protection of neurons from glutamate toxicity. Mol Cell Neurosci 2000; 15: 465-75.
10. Dogrukol-Ak D, Banks W A, Tuncel N, Tuncel M. Passage of vasoactive intestinal peptide across the blood-brain-barrier. Peptides 2003; 24: 437-44.
11. Uchida D, Arimura A, Somogyuari-Vigh A, Shioda S, Banks W. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 1996; 736: 280-6.
12. Banks WA, Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S. Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann NY Acad Sci 1996; 805: 270-9.
13. Dohi K, Mizushima H, Nakajo S, Ohtaki H, Matsunaga S, Shioda S. Pituatary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apotosis by inhibiting JNK/SAPK and p 38 signal transduction pathways. Regul Pep 2002; 109: 83-8.
14. Villalba M, Bockaert J, Journot L. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apotosis by activating the Mitogen-Activated Protein Kinase (MAP Kinase) pathway. J Neurosci 1997; 17: 83-90.
15. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozics T, Arimura A. Delayed systemic administration of PACAP 38 Is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000; 31: 1411-7.
16. Sheng H, Bart RD, Oury TD, Pearlstein RD, Crapo JD, Warner DS. Mice overexpressing extracellular Superoxide dismutase have increased resistance to focal cerebral ischemia. Neuroscience 1999; 88: 185-91.